Naivek, a peptide fusion bio-specialized company, announced on the 14th that it will present research results on the expansion of indications for its core pipeline ‘NP-201’ as an obesity treatment at the 'Pharma Partnering Summit' held in Boston, USA. Along with this, the company will also introduce the development status for existing indications such as pulmonary fibrosis, inflammatory bowel disease, and pulmonary arterial hypertension.
At this summit, Naivek will reveal the obesity treatment mechanism of NP-201 through the inhibition of fat accumulation and the long-lasting sustainable formulation platform based on this mechanism. NP-201 is expected to provide various treatment options to patients as it shows high efficacy not only when administered alone but also in combination with other therapies.
The body fat reduction effect of NP-201 is more than 10% superior to existing obesity treatments such as ‘Saxenda’ and ‘Wegovy,’ and it is particularly characterized by the ability to reduce weight without muscle loss. The company explained that this represents a differentiated competitive advantage as it offers obese patients the possibility to simultaneously achieve two important treatment goals: weight loss and muscle maintenance.
A Naivek representative stated, “NP-201 is a peptide-based therapeutic with regenerative mechanisms that can be applied to various diseases,” and added, “This summit presentation will be an important turning point in expanding the indications of NP-201 from its existing development as a treatment for pulmonary fibrosis, inflammatory bowel disease, and pulmonary arterial hypertension to obesity treatment.”
He continued, “We will strengthen partnerships with global pharmaceutical companies through this summit,” and added, “Since NP-201 is at a critical stage of entering clinical trials with the U.S. FDA as a treatment for inflammatory bowel disease, we plan to accelerate commercialization discussions with global companies.”
The Pharma Partnering Summit is a global event where pharmaceutical companies, biotech firms, research institutions, and investors seek partnership and collaboration opportunities. This event will be held from the 16th (local time), and active exchanges among participants are expected in areas such as open innovation, licensing and technology transfer, R&D collaboration, and investment.
Naivek successfully completed a global Phase 1 clinical trial for NP-201 as a treatment for pulmonary fibrosis in October last year. Due to its regenerative effects on damaged lung tissue as well as fibrosis inhibition, it has attracted attention from global pharmaceutical companies. Currently, Naivek is expanding the indications of NP-201 and is preparing to enter clinical trials with the U.S. FDA as a treatment for inflammatory bowel disease.
Recently, NP-201 also demonstrated excellent efficacy in preclinical trials for pulmonary arterial hypertension. In animal experiments induced with pulmonary arterial hypertension, it showed dose-dependent reductions in systolic blood pressure, diastolic blood pressure, and mean blood pressure, and the regenerative mechanism restoring vascular thickness to normal was also confirmed.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
